Business Wire

Octant Launches Polypharmacology Drug Discovery Engine for Complex Diseases with $30 Million Series A Financing Led by Andreessen Horowitz

EMERYVILLE, Calif.--(BUSINESS WIRE)--Octant, Inc., a synthetic biology drug discovery company designing small molecule, multi-target drug leads for multifactorial diseases announced that it has raised ...
Business Wire

Octant Raises $80 Million Series B Round to Support Expansion of Next-Generation Drug Discovery Platform, Announces Collaboration with Bristol Myers Squibb and Key Appointments

EMERYVILLE, Calif.--(BUSINESS WIRE)--Octant, Inc. (“Octant” or the “Company”), a next-generation, data-driven therapeutics company developing programmable biology and chemistry to build precision ...
Yahoo Finance

Zymergen Expands Agreement with Octant to Scale Next-Generation Drug Discovery Platform

EMERYVILLE, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”) today announced it has expanded its agreement with Octant to further scale their next-generation ...
Yahoo Finance

Zymergen Sells Modular Automation System to Octant to Scale Next-Generation Drug Discovery Platform

EMERYVILLE, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”), today announced it has entered into an agreement with Octant for the sale of a modular automation ...
TechCrunch

Emerging from stealth, Octant is bringing the tools of synthetic biology to large scale drug discovery

Octant, a company backed by Andreessen Horowitz just now unveiling itself publicly to the world, is using the tools of synthetic biology to buck the latest trends in drug discovery. As the ...